Navigation Links
Two New Jersey Hormone Therapy Lawsuits Dismissed
Date:7/14/2008

MADISON, N.J., July 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that Judge Jamie D. Happas of the New Jersey Superior Court in New Brunswick has granted Wyeth's motion for summary judgment in two hormone therapy cases that were scheduled for trial later this year. The court dismissed the cases of Bailey v. Wyeth, which was to have begun on September 15, and DeBoard v. Wyeth, which had an October 27 trial date. The plaintiffs in both cases alleged they developed breast cancer as a result of the use of Prempro(TM) and Premarin(R), hormone therapy products marketed by Wyeth, as well as Provera(R), a progestin product marketed by Upjohn.

In granting the motions, Judge Happas ruled, among other things, that the plaintiffs "failed to provide the specific type of evidence necessary to overcome the presumption of adequacy afforded [to] FDA-approved labeling" by New Jersey law and that the warnings were "adequate as a matter of law."

"We believe the court's ruling was a proper application of New Jersey law and is consistent with a growing body of law around the nation, rejecting challenges to FDA-approved labeling," says Lauren E. Handler, a partner with Porzio Bromberg & Newman, P.C., a New Jersey-based firm representing Wyeth in both cases.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Chemical Industry Has Decided to Gather at ChemOutsourcing Show on September 7-9 in New Jersey
2. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
3. E. coli Outbreak in New Jersey?
4. API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey
5. Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey
6. StemCyte Locates East Coast Operations in New Jersey
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Novo Nordisk Expands U.S. Headquarters in New Jersey
9. BioSpace New Jersey Career Fair Attracts Over 1,000 Bioscience Candidates
10. NicOx Opens U.S. Headquarters in New Jersey
11. Secure Symbology: Making New Jersey Proud While Saving Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... --  Invitae Corporation (NYSE: NVTA), one of the ... of the company,s management team will present at the ... Monday, March 6, 2017 at approximately 4:00 p.m. Eastern ... . The live, listen-only webcast ... investors section of the company,s website at ir.invitae.com ...
(Date:2/20/2017)... ... February 20, 2017 , ... Global relationship ... been approved for full, active membership in the Canadian Direct Sellers Association (DSA) ... Chief Executive Officer Jeff Olson in 2011. Today Nerium International, with ...
(Date:2/20/2017)...  This Report analyzes the worldwide markets for Bioinformatics in US$ ... separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and ... http://www.reportlinker.com/p04707099-summary/view-report.html ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:2/20/2017)... Salford, United Kingdom (PRWEB) , ... February 20, ... ... staff and manufactures industrial metal detection solutions for the food and pharmaceutical processing ... Consultants. This award goes to the manufacturer that has done the most or ...
Breaking Biology Technology:
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
Breaking Biology News(10 mins):